ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial
By
ASCO 2022 Conference Coverage
FEATURING
Laura Spring
By
ASCO 2022 Conference Coverage
FEATURING
Laura Spring
27 views
June 21, 2022
Login to view comments.
Click here to Login
Breast